These were based on surveys/interviews evaluating the impact of genetic testing for BRCA1/2 that used various patient-reported outcome measures (e.g., the Cancer Worry Scale, Hospital Anxiety and Depression Scale) at different time points. This evidence concerns the gene BRCA1 and major depressive disorder.